Aiming Higher – Changing the Course of Cancer

An article published on 19 May in the respected medical journal NEJM emphasizes that the course and perception of cancer are changing. We wanted to summarize the striking parts of this noteworthy article for you.
“We are talking about prevention and early diagnosis. I believe we can find answers and come up with game-changing treatments and get them to the people who need them. We have a chance to change the course.” United States Vice President Joe Biden, 1 January 2016.
Cancer is hundreds of diseases. Biomedical research has made some completely treatable (most childhood leukemias and Hodgkin lymphomas), and significant progress has been made in treating the remaining cancers. Indeed, over more than the last quarter-century, cancer mortality rates in America alone have fallen 23%, drugs discovered have saved approximately 1.7 million lives and prevented immeasurable suffering. Much of this success was achieved through strong, sustained federal investment and advances in scientific research. Still, more progress is needed. Cancer is the second leading cause of death in America and most developed countries, and in 2016 approximately 600.000 Americans are expected to die from cancer. That means an average of 1600 people every day.
For new initiatives, President Obama’s call, with Vice President Biden’s leadership, to reinvigorate cancer efforts is not the first comprehensive anticancer campaign. President Richard Nixon actually declared “war on cancer” in 1971. This raises questions about why such an initiative is being undertaken now and how today differs from 45 years ago.
We believe the time is right to reignite this fight against cancer because the convergence of new scientific understanding, technological innovation and expectations of success is greater than ever. Scientific and technological advances have significantly changed our understanding of cancer. Human Genome Projecttools and technologies were used in research, while data obtained from the Cancer Genome Atlasand other research explained that cancer is a genetic (gene-related) disease. Clearly, knowing what drives mutation in an existing tumor is more important than knowing which organ system it originates from. Also, although each tumor is molecularly unique, genomic technology has shown that certain pathways repeatedly exert effects (new “targeted” drugs directed at these pathways are a product of this knowledge).
Another rapidly developing research area looks beyond tumor cells to other factors frequently influencing tumor progression, such as stromal (supporting tissue) and immune cells in the tumor microenvironment. Thus, tumors have now been discovered to communicate and interact closely with surrounding tissue. Powerful new bioinformatics tools and methods also enable analysis and management of the many complex molecular and clinical data, or “big data,” needed to create predictive models of cancer progression and treatment response.
Meanwhile, after decades of struggle, strategies activating the immune system to attack cancer cells have achieved striking successes. Certain approaches, such as checkpoint inhibitors and chimeric antigen receptor T cell treatments, are immunotherapiesthat cause remission or even treat resistant forms of melanoma, leukemia and lymphoma, advanced mesothelioma and ovarian, lung, kidney and triple-negative breast cancers. However, many solid tumors fail to respond well to this approach, and initial positive responses do not always persist. Much work remains.
Undoubtedly, translating recent advances in understanding cancer biology into developing and applying new treatment approaches and making progress in cancer prevention, imaging and early diagnosis is highly challenging. New cancer research initiatives aim to make a difference across all fields by identifying two crucial priorities. These priorities are increasing resources devoted to fighting cancer and uniting nongovernmental organizations active in this area. This effort was developed by the government in the United States and is led personally by the Vice President.
Major topics in the new United States-led cancer program include developing cancer vaccines, early diagnosis technology, single-cell genomic examination, immunotherapy, focusing on childhood cancers and increasing information sharing.
Another important issue is the disadvantage rural areas face in cancer prevention, imaging and access to treatment, and initiating efforts to overcome this imbalance.
Another important aim of these initiatives is removing barriers that prevent information sharing and cooperation among different groups fighting cancer.
Although work on all these continues, one goal of this new initiative has become certain: inspiring a new generation of forward-looking individuals to challenge limitations in current cancer knowledge. Unleashing the scientific community’s abilities by providing strong, steadily flowing resources should facilitate biomedical research to accelerate progress in the fight against cancer. We hope efforts will be made to prepare infrastructure for advances in prevention, treatment and cure of all cancer types.
Sources
Aiming High — Changing the Trajectory for Cancer.
N Engl J Med 2016; 374:1901-1904May 19, 2016DOI: 10.1056/NEJMp1600894
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.